Combination chemotherapy (CISCA) for advanced urinary tract carcinoma. A preliminary report.
Twelve patients with metastatic transitional cell carcinoma from the urinary bladder were treated with a combination chemotherapy program consisting of cisplatinum, cyclophosphamide, and doxorubicin hydrochloride (CISCA). Ten patients had conditions for which a response to therapy could be determined, and nine achieved an objective response (one complete response, eight partial responses). Two additional patients with metastatic transitional cell carcinoma from the renal pelvis were also treated, and one achieved a partial response. In our experience, CISCA combination chemotherapy has given the highest response rate of any protocol thus far tested in advanced, metastatic urinary tract carcinoma.
D000368:Aged; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy*; D002945:Cisplatin / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000627:therapeutic use*; D004317:Doxorubicin / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D007680:Kidney Neoplasms / Q000188:drug therapy; D007682:Kidney Pelvis; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy; D014565:Urogenital Neoplasms / Q000188:drug therapy*
D004317:Doxorubicin; D003520:Cyclophosphamide; D002945:Cisplatin